Octreotide Depot (Teva)™

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Acromegaly For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with octreotide. Octreotide Depot is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours For the relief of symptoms associated with the following functional tumours of the gastro-enteropancreatic endocrine system: Carcinoid tumours with features of the carcinoid syndrome Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with octreotide Octreotide Depot is not curative in these patients.,Advanced Neuroendocrine Tumours of the Midgut Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Source: ARTG

• Shelf lifetime is 36 Months
• Store at 2 to 8 degrees Celsius
• Protect from Light; Do not Freeze

Source: ARTG

Composite pack

This medicine is a pack that contains more than one component.

Important: The components listed below are not necessarily in order of use. Please refer to the Consumer Medicine Information (CMI) or consult your doctor for proper administration instructions and sequence.

Component

• Injection, diluent for
• Intramuscular
• The vehicle is a clear, colourless to slightly yellow or brown solution.

Component

• Injection, modified release
• Intramuscular
• The powder is a white to white with yellowish tint.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 x 8 mL vial of powder with 1 x 3 mL pre-filled syringe of diluent

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: Octreotide

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).